Alterity Therapeutics
ATHE
8 hedge funds and large institutions have $503K invested in Alterity Therapeutics in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 4 closing their positions.
21% more capital invested
Capital invested by funds: $415K → $503K (+$88K)
0% less ownership
Funds ownership: 0.01% → 0% (-0%)
27% less funds holding
Funds holding: 11 → 8 (-3)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$681 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$56.9K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$16K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$13.7K |
| 4 |
CA
Claro Advisors
Boston,
Massachusetts
|
-$5K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Morgan Stanley
New York
| $411K | +$681 | +40 | +0.2% |
|
|
2
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $79K | -$56.9K | -3,346 | -45% |
|
|
AG
3
Advisor Group
Phoenix,
Arizona
| $5K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $4K | -$13.7K | -804 | -80% |
|
|
AIM
5
Advantage Investment Management
Cedar Rapids,
Iowa
| $2K | – | – | – |
|
|
NFG
6
Next Financial Group
Houston,
Texas
| $1K | – | – | – |
|
|
NFH
7
NEXT Financial Holdings
Houston,
Texas
| $1K | +$987 | +58 | New |
|
|
APA
8
American Portfolios Advisors
Holbrook,
New York
| $156 | – | – | – |
|
|
9
Citadel Advisors
Miami,
Florida
| – | -$16K | -1,274 | Closed |
|
|
CA
10
Claro Advisors
Boston,
Massachusetts
| – | -$5K | -224 | Closed |
|
ATHE Hedge Fund Activity: Q1 2019 in Review
8 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q1 2019, worth a combined $503K — up 21% from $415K a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ATHE and 1 opened new positions — a net loss of 3 holders — while 2 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $681. The largest seller was Susquehanna International Group, cutting an estimated $56.9K.
- 8 institutional investors held Alterity Therapeutics (ATHE) as of Q1 2019, down from 11 in Q4 2018.
- Funds reported $503K of Alterity Therapeutics stock for Q1 2019, up 21% quarter-over-quarter.
- 1 fund opened new Alterity Therapeutics positions in Q1 2019 and 4 closed out, a net change of -3 holders.
- The largest Alterity Therapeutics buyer in Q1 2019 was Morgan Stanley, an estimated $681 added.
- The largest Alterity Therapeutics seller in Q1 2019 was Susquehanna International Group, an estimated $56.9K sold.
Based on aggregated 13F filings for Q1 2019.